Capital World Investors
RVNC

Capital World Investors’s Revance Therapeutics, Inc. RVNC Stock Holding History

Capital World Investors’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-13,938,589
Closed -$35.8M – 566
2024
Q2 		$35.8M Sell
13,938,589
-6,946
-0% -$23.7K 0.01% 413
2024
Q1 		$68.6M Buy
13,945,535
+2,006,459
+17% +$11.9M 0.01% 372
2023
Q4 		$105M Sell
11,939,076
-21,744
-0.2% -$178K 0.02% 337
2023
Q3 		$137M Buy
11,960,820
+2,385,946
+25% +$45.9M 0.03% 301
2023
Q2 		$242M Sell
9,574,874
-501,227
-5% -$15.6M 0.05% 252
2023
Q1 		$325M Buy
10,076,101
+595,945
+6% +$18.6M 0.07% 232
2022
Q4 		$175M Buy
9,480,156
+1,431,318
+18% +$32.7M 0.04% 291
2022
Q3 		$217M Buy
8,048,838
+3,458,838
+75% +$70.2M 0.05% 261
2022
Q2 		$63.4M Buy
4,590,000
+1,240,000
+37% +$19.1M 0.01% 371
2022
Q1 		$65.3M Sell
3,350,000
-362,000
-10% -$5.49M 0.01% 396
2021
Q4 		$60.6M Buy
3,712,000
+745,000
+25% +$12.4M 0.01% 419
2021
Q3 		$82.7M Hold
2,967,000
– – 0.01% 388
2021
Q2 		$87.9M Buy
2,967,000
+395,898
+15% +$11.4M 0.01% 394
2021
Q1 		$71.9M Buy
2,571,102
+441,102
+21% +$12.2M 0.01% 397
2020
Q4 		$60.4M Hold
2,130,000
– – 0.01% 396
2020
Q3 		$53.5M Hold
2,130,000
– – 0.01% 387
2020
Q2 		$52M Hold
2,130,000
– – 0.01% 363
2020
Q1 		$31.5M Hold
2,130,000
– – 0.01% 360
2019
Q4 		$34.6M Buy
2,130,000
+445,000
+26% +$6.9M 0.01% 376
2019
Q3 		$21.9M Hold
1,685,000
– – 0.01% 400
2019
Q2 		$21.9M Hold
1,685,000
– – 0.01% 431
2019
Q1 		$26.6M Buy
1,685,000
+460,000
+38% +$7.98M 0.01% 406
2018
Q4 		$24.7M Hold
1,225,000
– – 0.01% 415
2018
Q3 		$30.4M Sell
1,225,000
-210,000
-15% -$5.71M 0.01% 428
2018
Q2 		$39.4M Buy
+1,435,000
New +$43.1M 0.01% 389

Other funds holding RVNC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return

Capital World Investors's RVNC Position: Q3 2024 in Review

Capital World Investors sold out of Revance Therapeutics, Inc. (RVNC) in Q3 2024, closing a stake of 13,938,589 shares — an estimated $35.8M sold.

Capital World Investors first reported a position in RVNC in Q2 2018 and held it in 25 quarters. The position peaked at $325M in Q1 2023. 201 funds tracked by Wall St. Rank hold RVNC as of Q3 2024.

  • Capital World Investors reported no remaining Revance Therapeutics, Inc. position as of Q3 2024 after selling out during the quarter.
  • Capital World Investors sold 13,938,589 Revance Therapeutics, Inc. shares in Q3 2024, an estimated $35.8M.
  • Capital World Investors first reported a position in Revance Therapeutics, Inc. in Q2 2018 and held it in 25 quarters.
  • Capital World Investors's Revance Therapeutics, Inc. position peaked at $325M in Q1 2023.
  • 201 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2024.

Based on Capital World Investors's 13F filing for Q3 2024, filed 13 Nov 2024.